Omeros (NASDAQ:OMER) Sets New 52-Week High Following Better-Than-Expected Earnings

Key Points

• Omeros shares surged 24.6% to a new 52-week high of $18.14 after the company reported quarterly EPS of $0.02, beating the expected $0.27 loss, while revenue of $28.53 million more than doubled analyst expectations.
• Management highlighted strong early demand for YARTEMLEA, reduced C5 competition, debt reduction and share repurchases as key growth and financial catalysts.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and average price target of $38, although some firms recently downgraded the stock to “Hold.”

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) reached a new 52-week high during mid-day trading on Thursday following a stronger than expected earnings report. The company traded as high as $18.14 and last traded at $17.2010, with a volume of 3092745 shares changing hands. The stock had previously closed at $13.71.

The biopharmaceutical company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analysts' expectations of $12.69 million.

Key Headlines Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Significant earnings and revenue beats: Omeros reported second-quarter earnings of $0.02 per share, versus analysts’ expected loss of $0.27 per share and a $0.53 loss a year earlier. Revenue reached $28.53 million, more than double the $12.69 million consensus estimate. The results improved investor confidence in the company’s commercial performance. Omeros Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: YARTEMLEA momentum is supporting the outlook: Management highlighted strong early demand for YARTEMLEA, which is becoming an important commercial growth driver. Analysts also cited reduced competition in the C5 market as a positive factor for the product’s potential. Omeros Earnings Call: Yartemlia Surge and Leaner Balance Sheet
• Positive Sentiment: Balance-sheet and shareholder actions added to the catalyst: The earnings update emphasized debt reduction and a leaner balance sheet, while share repurchases provided an additional potential source of per-share support. OMER Stock Soars After YARTEMLEA Sales Momentum, Debt Reduction and Share Buybacks
• Positive Sentiment: Analyst remains bullish: H.C. Wainwright reiterated its Buy rating and maintained a $33 price target, citing YARTEMLEA’s launch trajectory and reduced C5 competition. This target is well above the stock’s recent trading range and reinforces the bullish reaction to the results. Omeros Maintained at Buy With $33 Price Target
• Neutral Sentiment: Reported short-interest data showed zero shares sold short, offering no meaningful short-squeeze or bearish-positioning signal.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Zacks Research downgraded Omeros from a "strong-buy" rating to a "hold" rating in a report on Monday, July 13th. Wall Street Zen downgraded Omeros from a "buy" rating to a "hold" rating in a report on Sunday, June 7th. D. Boral Capital reissued a "buy" rating and set a $36.00 price target on shares of Omeros in a report on Tuesday, April 21st. Weiss Ratings raised shares of Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. Finally, HC Wainwright reissued a "buy" rating on shares of Omeros in a report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $38.00.

Insider Buying and Selling at Omeros

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the company's stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the transaction, the director directly owned 35,067 shares in the company, valued at $407,127.87. This represents a 17.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC purchased a new stake in Omeros during the 1st quarter worth approximately $357,000. XTX Topco Ltd purchased a new stake in shares of Omeros in the second quarter valued at approximately $191,000. Invesco Ltd. raised its position in Omeros by 34.1% during the second quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company's stock worth $350,000 after acquiring an additional 29,644 shares during the period. Marshall Wace LLP lifted its stake in Omeros by 15.1% in the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company's stock valued at $2,224,000 after buying an additional 97,224 shares in the last quarter. Finally, Sei Investments Co. purchased a new position in shares of Omeros in the second quarter valued at approximately $40,000. Hedge funds and other institutional investors own 48.79% of the company's stock.

Omeros Trading Up 24.6%

The stock's fifty day simple moving average is $10.60 and its 200 day simple moving average is $11.47. The company has a market cap of $1.24 billion, a price-to-earnings ratio of 24.53 and a beta of 2.54.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source